Sumitomo Mitsui Trust Group Inc. Buys 18,160 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sumitomo Mitsui Trust Group Inc. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,104,441 shares of the medical research company's stock after acquiring an additional 18,160 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.29% of Thermo Fisher Scientific worth $683,174,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in TMO. Signature Resources Capital Management LLC grew its position in shares of Thermo Fisher Scientific by 318.2% in the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after buying an additional 35 shares during the last quarter. New Millennium Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $29,000. Stephens Consulting LLC grew its holdings in shares of Thermo Fisher Scientific by 116.0% in the second quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock valued at $30,000 after purchasing an additional 29 shares during the period. Headlands Technologies LLC purchased a new position in Thermo Fisher Scientific during the first quarter worth about $32,000. Finally, Bank & Trust Co purchased a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $33,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares of the company's stock, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,150 shares of company stock valued at $15,676,125. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 0.6 %

Shares of TMO traded down $3.32 during midday trading on Tuesday, reaching $543.60. The stock had a trading volume of 729,116 shares, compared to its average volume of 1,457,989. Thermo Fisher Scientific Inc. has a 1-year low of $439.11 and a 1-year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market cap of $207.93 billion, a price-to-earnings ratio of 34.29, a PEG ratio of 3.65 and a beta of 0.79. The company's fifty day simple moving average is $592.59 and its two-hundred day simple moving average is $583.56.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.69 earnings per share. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.78%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TMO shares. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an "overweight" rating in a report on Friday, September 20th. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Barclays decreased their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a report on Wednesday, October 23rd. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating for the company in a research note on Thursday, October 24th. Finally, Sanford C. Bernstein decreased their price target on Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating for the company in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $649.33.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.